RESUMEN
This study investigated the application effect of contrast-enhanced ultrasound (CEUS) and enhanced CT in diagnosis of liver cancer and response evaluation of radiofrequency ablation (RFA). A total of 60 patients with liver cancer were selected in Dongying People's Hospital from April 2016 to May 2017. All patients were subjected to CEUS and enhanced CT. With pathological examination as the gold standard, diagnostic consistency of the two methods was compared. After RFA, patients were subjected to CEUS and enhanced CT to assess the efficacy, and the consistency was compared. There was no significant difference in diagnostic accuracy between CEUS and CT (p>0.05). Area under the ROC curve of CEUS was 0.896, with a sensitivity of 91.2% and a specificity of 88.7%. The area under the ROC curve for enhanced CT diagnosis was 0.907, with a sensitivity of 91.8% and a specificity of 89.7%. No significant difference in the maximal cross sectional area of lesions was found between CEUS and enhanced CT, and there was no significant difference in evaluation of therapeutic efficiency between the methods (p>0.05) before and 1 and 3 months after treatment. Bland-Altman test showed that there was a strong consistency between CEUS and enhanced CT in the measured maximum cross-sectional area of lesions at 1 and 3 months after treatment. Linear regression analysis showed that maximum section cross-sectional area measured by CEUS was significantly correlated with that detected by enhanced CT (r2=0.617). The results suggested that diagnostic efficiency of CEUS was similar to that of enhanced CT, and both showed high sensitivity and specificity. Two methods showed high consistency in evaluating the curative effect of RFA. CEUS can achieve real-time observation of focal blood flow perfusion, and was more economically affordable and convenient.
RESUMEN
Correlation between CT features of adrenocortical and adrenal medullary tumors and the expression of miR-96 in serum were investigated. A total of 230 patients with adrenocortical tumors and 194 patients with adrenal medullary tumors were selected in Dongying People's Hospital from August 2013 to August 2017. The two groups of patients underwent CT examination, and the signs and symptoms were recorded. The expression of miR-96 in the serum of the two groups was detected by RT-PCR, and the correlation between the expression of serum miR-96 and CT features was analyzed. In patients with adrenocortical tumor, serum miR-96 expression levels were significantly higher in patients with tumor diameter ≥5 cm than those with tumor diameter <5 cm (p<0.001). In patients with adrenal medullary tumor, serum miR-96 expression levels were significantly higher in patients with tumor diameter ≥3 cm than those with tumor diameter <3 cm (p<0.001). In patients with adrenocortical or adrenal medullary tumor, serum miR-96 expression levels were significantly higher in patients with peripheral infiltration than those without peripheral infiltration (p<0.001), and serum miR-96 expression levels were also significantly higher in patients with distant metastasis than those without distant metastasis (p<0.001). Serum levels of miR-96 in patients with benign adrenocortical and adrenal medullary tumors were significantly lower than those with malignant tumors in the same group (p<0.001). miR-96 may have oncogenic functions in patients with adrenocortical or adrenal medullary tumors. Increased expression level of miR-96 may promote proliferation, invasion and metastasis of tumors, and serum levels of miR-96 provide references for the diagnosis of adrenocortical and adrenal medullary tumors.
